Clinical Trial Update: A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the effects of immediate-release paliperidone on QT and QTc intervals in patients with schizophrenia or schizoaffective disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Paliperidone (immediate release) (paliperidone)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1 | Status: COMPLETED